Ritter Pharmaceuticals Inc (NASDAQ:RTTR) shares traded down 5.1% during trading on Friday . The company traded as low as $0.80 and last traded at $0.93. 1,500 shares changed hands during trading, a decline of 99% from the average session volume of 101,750 shares. The stock had previously closed at $0.98.
A number of research analysts have recently commented on the company. HC Wainwright reissued a “buy” rating and set a $15.00 price objective on shares of Ritter Pharmaceuticals in a report on Wednesday, August 15th. ValuEngine lowered Ritter Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, October 29th. Finally, Zacks Investment Research raised Ritter Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, August 1st.
The stock has a market capitalization of $5.87 million, a P/E ratio of -0.18 and a beta of 1.21.
In related news, Director Matthew W. Foehr bought 19,751 shares of the business’s stock in a transaction that occurred on Friday, August 17th. The stock was acquired at an average price of $2.04 per share, for a total transaction of $40,292.04. Following the transaction, the director now directly owns 54,751 shares of the company’s stock, valued at $111,692.04. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 21.60% of the stock is owned by company insiders.
Ritter Pharmaceuticals Company Profile (NASDAQ:RTTR)
Ritter Pharmaceuticals, Inc develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance.
Read More: Dividend Aristocrat Index
Receive News & Ratings for Ritter Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.